gsk2831781
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 30, 2014 (NCT02195349)
Timeline
Indications
Mechanism of action
- Lymphocyte activation gene 3 proteinINHIBITOR
LAG3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk2831781
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03965533 | Phase 1 | Jun 14, 2019 | GlaxoSmithKline |
| NCT03893565 | Phase 2 | May 6, 2019 | GlaxoSmithKline |
| NCT02195349 | Phase 1 | Jul 30, 2014 | GlaxoSmithKline, Parexel |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 2014 |
| Parexel | For profit | 1 | 0 | 1 | 2014 |
2 organizations
Page 1 / 1